Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055809 | 1.00 | HRH4 (0.53) | HRH4ALOX15HPGDKDM4EALDH1A1 | |
| SCHEMBL4044128 | 0.91 | ALOX15 (0.50) | HRH4ALOX15HPGDKDM4EALDH1A1 | |
| SCHEMBL3276933 | 0.90 | ALOX15 (0.47) | HRH4ALOX15HPGDKDM4EALDH1A1 | |
| SCHEMBL4042473 | 0.89 | ALDH1A1 (0.50) | ALOX15HPGDKDM4EALDH1A1RAB9A | |
| SCHEMBL24113196 | 0.86 | ALOX15 (0.46) | HRH4ALOX15HPGDKDM4EALDH1A1 | |
| SCHEMBL28459983 | 0.84 | ALDH1A1 (0.46) | ALOX15HPGDKDM4EALDH1A1RAB9A | |
| SCHEMBL8318032 | 0.84 | CDK1 (0.54) | ALOX15HPGDKDM4EALDH1A1RAB9A | |
| SCHEMBL22621694 | 0.82 | ALOX15 (0.45) | ALOX15HPGDKDM4EALDH1A1RAB9A | |
| SCHEMBL28455876 | 0.82 | ALOX15 (0.45) | HRH4ALOX15HPGDKDM4EALDH1A1 | |
| SCHEMBL5357191 | 0.82 | CDK1 (0.52) | HRH4ALOX15HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| EP-4107157-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-115380033-A | SETD2 inhibitors and related methods and uses, including combination therapies | EPIZYME股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3837240-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112585119-A | Substituted indoles and methods of use thereof | EPIZYME股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | HRH4 457/4885ALOX15 2532/4885HPGD 1390/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | HRH4 530/4885ALOX15 2478/4885HPGD 1346/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | HRH4 4351/4885ALOX15 4835/4885HPGD 4565/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | HRH4 3102/4885ALOX15 3392/4885HPGD 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.